UCB today announced that Vimpat (lacosamide) (CV), a new antiepileptic drug (AED) is available in the US as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older.
Vimpat will be available in US pharmacies by the first week of June 2009.
“The availability of Vimpat in the US is an important milestone for people living with epilepsy and for UCB,” said Rich Denness, Vice-President and General Manager CNS US, UCB.
“Bringing Vimpat to US patients underscores UCB’s commitment to the epilepsy community and UCB’s leadership position in this disease state.”
Epilepsy affects approximately six million people in the US, Japan, UK, France, Germany, Italy and Spain, and it can strike anyone at anytime.
“Lacosamide provides new hope in helping patients move closer to the goal of seizure freedom,” said Steven S Chung, MD, Director of Clinical Epilepsy Research at Barrow Neurological Institute in Phoenix.
“Lacosamide can help patients across the treatment paradigm, from those recently diagnosed who have not achieved seizure control on current therapy, to those who have tried a variety of medications and are still suffering from frequent seizures.”